Georiga Bio sign-on to the State Medical Technology Alliance (SMTA) letter to U.S. Department of Health and Human Services (HHS) and Centers for Medicare & Medicaid. Please see the language below.
The Honorable Alex M. Azar II
U.S. Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201
The Honorable Seema Verma
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Dear Secretary Azar and Administrator Verma:
As members of the State Medical Technology Alliance (SMTA), we are state and regional life sciences associations representing biotechnology, medical device companies, universities, research institutions, and venture capital firms across the country, all dedicated to developing and delivering life-enhancing and life-saving products, we write to express our strong support for your leadership in the U.S. Department of Health and Human Services’ (HHS) efforts to provide coverage for transformative medical devices that are approved as breakthrough devices by the FDA.
The COVID-19 pandemic highlighted the need for our nation’s health care system to better align care for patients. We commend HHS for taking swift action to create appropriate waivers and incentives across different health care stakeholders to better address this devastating disease. Providing patients with access to breakthrough devices would further this push to align care for patients by promoting innovation and providing patients with the latest in life-changing medical technology.
The medical technology industry is an important and thriving sector in the U.S. economy, creating jobs in all 50 states and representing a sizable portion of the nation’s Gross Domestic Product. The industry is responsible for about 1.9 million jobs in the U.S. and an economic output of approximately $381 billion annually.
Access to state-of-the art medical technology and diagnostics can help to improve care and patient outcomes, and CMS has acknowledged the value of breakthrough products by including a Breakthrough Product Pathway for new technology add-on payments (NTAP) in the Final Rule on the FY 2020 Inpatient Prospective Payment System.
We commend HHS and CMS for these efforts and urge you to take the next step by providing coverage for all medical devices that are approved and cleared as FDA-designated breakthrough in all settings. Providing this needed certainty will help ensure the next round of truly life-changing innovation can get to the patients who need them as quickly as possible.
As members of the SMTA, we look forward to working with the Administration to finalize this critical effort.
Arizona BioIndustry Association (AZBio)
Biocom: Life Science Association of California
Bioscience Association of West Virginia (BioWV)
California Life Sciences Association (CLSA)
Colorado BioScience Association (CBSA)
Florida Medical Manufacturers Consortium (FMMC)
Healthcare Institute of New Jersey (HINJ)
Illinois Biotechnology Innovation Organization (iBIO)
Indiana Health Industry Forum (IHIF)
Indiana Medical Device Manufacturers Council (IMDMC)
Iowa Biotechnology Association (IowaBio)
Kentucky Life Sciences Council
Life Sciences Pennsylvania
Life Science Tennessee
Life Science Washington
Massachusetts Medical Device Industry Council (MassMEDIC)
Medical Alley Association
MedTech Association New York
Michigan Biosciences Industry Association (MichBio)
Mississippi Biotechnology Association
Missouri Biotechnology Association (MOBIO)
Southeast Life Sciences
Texas Healthcare & Bioscience Institute (THBI)